MADISON,
WI--December 3, 2004--NimbleGen Systems Inc., producer of custom
high-density DNA microarrays using proprietary Maskless Array
Synthesis (MAS) technology, announces the name change of its Germany-based
chemistry R&D subsidiary, Chemogenix GmbH, to NimbleGen Systems
GmbH.
NimbleGen acquired Chemogenix in 2001 to strengthen their patent
and technology portfolio surrounding the in situ synthesis of
DNA microarrays. Chemogenix GmbH, formed in 2000 around technology
developed under the leadership of Dr. Wolfgang Pfleiderer, generates
technology that helps improve NimbleGen's core array technology
and enables new high-end product development.
"This
name change reflects the fact that while NimbleGen may be comprised
of several legal entities, we are all operating as one company
under a common name, regardless of whether we are located in the
US, Germany, Iceland or elsewhere," said Dr. Stan Rose, President
and CEO of NimbleGen. "It is our hope that this change will
further strengthen the NimbleGen brand in Europe, and that our
European customers will recognize that we have a prominent local
presence."
About
NimbleGen Systems Inc.
NimbleGen Systems (http://www.nimblegen.com/) is the leading supplier
of custom-designed high-density microarray products and services,
offering unprecedented flexibility for genomics research. NimbleGen's
Maskless Array Synthesis (MAS) technology combines photo-deposition
chemistry with digital light projection to shorten array fabrication
from months to hours. Customers benefit from extreme flexibility,
optimized array design, highly reproducible array fabrication
and statistically robust results-all with low cost and quick turnaround.
NimbleGen is working with scientists around the world to develop
and deploy a wide range of new microarray applications.
